Medical Oncology

Prostate Cancer

Questions discussed in this category

Is there any way to safely treat patients with mCRPC with 177-Lu PSMA who are on hemodialysis?

Can you give Pluvicto with concurrent palliative EBRT?

If so, do you modify your external beam dose?

When and how are you incorporating tumor sequencing to plan treatment of metastatic prostate cancer?

Given the FDA approvals for PARP inhibitors and combinations in mCRPC, when do you obtain NGS for mCRPC? Do you have a preferred assay?

5 Answers available

Do you use denosumab for castration-sensitive prostate cancer with osseous metastases?

Only the mCRPC population was included in the Fizazi et al. study, but the FDA approval is for prevention of skeletal related events from any solid tu...

4 Answers available

Is there adequate evidence for the use of PARPi in combination with ARSI for BRCA+/HRR mutated mCRPC as compared to sequential therapy?

3 Answers available

What is the optimal sequence of available therapies in patients with BRCA+/HRR mCRPC after progression on first line combinations?

If a patient has already received ADT+ARSI would you use PARPi over chemotherapy in 2nd line?

2 Answers available

Will prior novel hormonal therapy affect when/how you use olaparib plus abiraterone for patients with BRCA-mutated metastatic castration resistant prostate cancer?

2 Answers available

Do you still order mpMRI for staging of prostate cancer in addition to PET-PSMA?

Which patients specifically benefit from both mpMRI and PET-PSMA?

4 Answers available

For patients who progress to mCRPC on ADT+ARSI started in mCSPC setting, do you continue the ARSI if patients have had a mixed response?

ARSI may be controlling a hormone sensitive clone. Some patients flare after stopping the drug.

1 Answer available

Would you extrapolate from EMBARK to use an ARPI other than enzalutamide in high risk biochemically recurrent prostate cancer for a patient with contraindications to enzalutamide?

1 Answer available

With multiple PARPi + ARSI combinations now approved, how are you selecting which combination to use for a patient with BRCA mutated mCRPC?

3 Answers available

Does the presence of ductal adenocarcinoma change how you risk stratify or treat patients with localized prostate cancer?

How would it change your risk group or management? Does Decipher help further inform treatment?

1 Answer available

Are there any scenarios in which you would consider use of PARPi in the upfront mCSPC setting rather than reserving for CRPC?

3 Answers available

Does a negative staging PSMA PET in a patient with biopsy-proven recurrent prostatic adenocarcinoma change your management?

I have a pair of patients with MRI+ and biopsy+ disease who have staging PSMA PET/CT that do not show disease within the prostate (or anywhere else).&...

2 Answers available

How do you manage de novo high volume mCSPC with both BRCA2 mutation and MSI-H on somatic testing?

When (if ever) would you consider immune checkpoint inhibitor up front? Would you be less inclined to offer triple drug therapy? (Some thought that ta...

1 Answer available

How do you manage hot flashes in men with prostate cancer on androgen deprivation therapy?

16 Answers available

Can you/do you use an androgen receptor blocker alone in patients with metastatic hormone-sensitive prostate cancer who cannot tolerate GnRH-directed therapy?

7 Answers available

How would you manage a patient with mCRPC with a good clinical and >50% reduction in PSA to Lu-PSMA but evidence of radiographic progression on PSMA PET/CT?

1 Answer available

How would you treat a patient presenting with de novo metastatic prostate cancer and baseline low testosterone?

If baseline testosterone is at castrate levels (e.g. <50), would you consider patient to have castrate-resistant disease?

1 Answer available

How would you treat margin positive, node positive (pN+) prostate cancer with detectable post-op PSA but negative PSMA-PET after radical perineal prostatectomy?

How does margin positive influence your decision?

1 Answer available

How do you manage dry eye related to Pluvicto Lu-177?

2 Answers available

How do you sequence Ra-223 and Lu-177 in patients with mCRPC with predominantly bony disease?

Do you preferentially use Ra-223 first given the RALU study?

1 Answer available

Is there a role for radiotherapy to the primary in high volume metastatic prostate cancer with well controlled disease on ADT?

1 Answer available

How do you manage drug-drug interactions between oral anticoagulants and the ARSI agents such as apalutamide and enzalutamide?

1 Answer available

How do you reconcile discrepancies in clinical prostate cancer staging with AJCC and NCCN?

In particular, in the modern era of multi-parametric prostate MRI and PSMA-PET, certain findings such as EPE, SVI, or pelvic lymphadenopathy may be no...

7 Answers available

For what duration should abiraterone be used in a patient with biochemical and pelvic node recurrence (N1M0) who had prior definitive therapy with either RP or RT?

Do you feel comfortable stopped abiraterone after 2 years?

2 Answers available

What is the minimum duration to be on bicalutamide prior to starting GnRH agonist in de novo metastatic prostate cancer with significant bone disease?

1 Answer available

Has use of PSMA PETCT revealed increased local failures than previously known after definitive prostate EBRT with biochemical failure?

3 Answers available

How do you treat localized prostate cancer with neuroendocrine differentiation?

4 Answers available

Do you always obtain PSMA PET as initial staging for high risk and very high risk localized prostate cancer patients?

6 Answers available

Would you consider adding abiraterone to ADT and salvage RT in a prostate cancer patient with pN1 disease at radical prostatectomy?

24 months ADT + abiraterone + definitive RT is indicated for cN1 disease but not for pN1 disease per NCCN. Can the data be extrapolated to this popula...

1 Answer available

In a patient with very high risk prostate cancer opting for prostatectomy, when, if ever, do you recommend neoadjuvant ADT?

4 Answers available

How aggressive would you be in irradiating asymptomatic bone metastases in a patient with metastatic prostate cancer?

Notably, the patient presented with renal failure due to ureteral obstruction and hydronephrosis, receives hemodialysis, and has limited systemic opti...

4 Answers available

What is the optimal duration of ADT for unfavorable intermediate risk or high risk localized prostate cancer treated with SBRT instead of conventionally fractionated or hypofractionated RT?

Do you also give neoadjuvant, concurrent, and adjuvant ADT in the same manner as for non-SBRT EBRT?

5 Answers available

How do you interpret PSMA/PET with focal prostate activity after XRT currently on ADT with stable PSA?

Pretreatment PSA 25.3 with Gleason 4+3=7 and MRI suspicious for ECE. Eight months after pelvic nodal and prostate XRT to 79 Gy, PSA is 5.02 (down from...

1 Answer available

Would you treat the prostate in a patient with widely metastatic disease who has CR to all metastatic sites after systemic therapy or ADT?

2 Answers available

Do you recommend prostate RT for patients with metastatic (M1) disease?

A recent NCBD analysis (Rusthoven et al., PMID 27325855) suggests that the addition of prostate RT significantly improves survival compared to AD...

8 Answers available

Would you consider adding abiraterone, in addition to ADT, for patients with less than very-high risk localized prostate cancer but high clinical-genomic metastasis risk after EBRT?

Specifically if metastatic risk estimate approached the failure rate in control arm of STAMPEDE for high-risk non-metastatic disease (69% MFS at 6 yea...

1 Answer available

Do you ever initiate on degarelix and then switch to leuprolide for patients with prostate cancer and cardiac risk factors receiving ADT?

If so, how long are they on degarelix before the switch?

2 Answers available

What is your approach to systemic treatment of de novo metastatic hormone-sensitive prostate ductal adenocarcinoma with lung only metastases?

1 Answer available

What systemic therapy do you recommend for prostate cancer pelvic nodal recurrence on PSMA PET-CT after prostatectomy and salvage radiation?

If ADT +/- ARPI + RT, what duration of systemic therapy do you recommend?

1 Answer available

Do you continue ADT/Lupron in all patients with castrate resistance prostate cancer?

Are there exceptions?

1 Answer available

How do you approach imaging in patients with M0 castration-resistant prostate cancer with rising PSA on an ARSI?

What imaging modality do you use (conventional, PSMA PET, etc.)? When do you image (ex: a PSA threshold or PSADT)?

1 Answer available

How do you approach a patient with prostate cancer with sclerotic/lytic lesions found on a CT scan but not seen on a bone scan or PET-PSMA?

Would you consider these as metastatic sites? Would you biopsy to confirm?

3 Answers available

Would you change AR signaling inhibitor in a patient with high volume metastatic castration-sensitive prostate cancer who started darolutamide with initial plan for docetaxel but in whom chemotherapy was eventually deferred?

Would you switch to enzalutamide or apalutamide if not giving docetaxel given darolutamide data for mCSPC is only from ARASENS trial with docetaxel?

1 Answer available

Does recent COVID-19 infection result in elevated PSA?

1 Answer available

Would you prescribe ADT or AR inhibitors for a patient with moderate to severe dementia who has biochemical recurrent, non-metastatic prostate cancer, but otherwise good physical performance status and prognosis >5 years?

Would you prescribe ADT for a patient with dementia who has biochemical recurrent, non-metastatic prostate cancer, but otherwise good physical PS?

2 Answers available

Has the recent presentation of RADICALS-HD changed your ADT duration recommendations for patients receiving post operative radiation therapy for prostate cancer after radical prostatectomy?

2 Answers available

How do you approach systemic therapy for metastatic prostate cancer in geriatric patient when progressed to mCRPC on ADT alone?

2 Answers available

Would you use abiraterone or docetaxel in addition to ADT and radiotherapy for patients with very high risk, node-negative prostate cancer?

2 Answers available

Did the approval of lutetium Lu 177 vipivotide tetraxetan (Pluvicto) change how you image and manage patients with metastatic castrate-resistant prostate cancer?

When do you order PSMA PET? Do you preferably order Locametz (gallium Ga 68 gozetotide) PET?

1 Answer available

Which imaging modality do you prefer when monitoring disease status for patients with prostate cancer undergoing 177-Lu PSMA treatment?

PSMA PET vs Conventional imaging vs combined imaging?

4 Answers available

How do you manage surveillance imaging for patients with metastatic castration-naive prostate cancer with an initial low PSA?

2 Answers available

How long after initiating ADT/androgen blockade is it acceptable to start docetaxel in a patient with high burden, de-novo metastatic HSPC where you are recommending triplet therapy?

1 Answer available

Would you consider bone antiresorptive therapy in mCRPC with only 1 lesion per PSMA scan?

1 Answer available

How do you define bone disease progression in mCRPC while on docetaxel?

Do you wait for radiographic progression? What is your preferred imaging modality for re-staging?

1 Answer available

In a patient with otherwise low-risk prostate cancer, does presence of a small component of Grade Group 3 disease up-stage to unfavorable intermediate?

How would you treat such a patient?

3 Answers available

Are you comfortable combining relugolix with enzalutamide or abiraterone?

Current NCCN guidelines recommended not combining relugolix with these agents until more data is available. Any drug interaction concerns or ot...

1 Answer available

Is there any role for ascertaining somatostatin-receptor status with a DOTATATE PET scan in prostatic adenocarcinoma with neuroendocrine features to consider lanreotide along with chemotherapy?

1 Answer available

What clinical and pathological features do you consider when deciding which androgen receptor targeted agent to combine with ADT for a patient with newly diagnosed castrate sensitive metastatic prostate cancer?

2 Answers available

How would you approach second line treatment for prostate adenocarcinoma with diffuse neuroendocrine features?

What would you use after platinum/taxane/IO first line therapy?

1 Answer available

For a patient with localized high risk prostate cancer with high risk Decipher score receiving ADT and abiraterone, is there any value of continuing ADT and abiraterone beyond two years?

2 Answers available

Would you consider SBRT for node negative small cell carcinoma of the prostate?

2 Answers available

What duration of ADT + abiraterone do you recommend prior to initiation of HDR brachytherapy followed by EBRT for very high risk localized cT3bN0 prostate cancer?

1 Answer available

How do you approach rising PSA many years after prostatectomy with negative PSMA PET?

4 Answers available

For a patient with PSMA+ mCRPC but relatively low SUV values, does that influence your decision to use 177Lu-PSMA or discussion with patient regarding potential benefit?

Would you use an FDG PET to further inform decision?

1 Answer available

How would you manage a patient with PSA relapse 10 years after salvage radiotherapy with PSA doubling time<6 months?

Would you treat with ADT if no metastatic disease? Does absolute PSA (e.g. PSA<2) inform decision?

1 Answer available

Do you hold ADT prior to biopsy of possible prostate cancer metastatic disease?

Does ADT affect the results of a biopsy?

1 Answer available

How would you work up a patient with prostate cancer with bone scan suspicious for metastatic disease and a negative PSMA PET/CT?

Additional imaging of the potential lesions, biopsy or assume negative given normal PSMA PET/CT.

7 Answers available

In patients who initially received chemo-hormonal first-line therapy for metastatic prostate cancer followed by abiraterone/enzalutamide for castration-resistant disease, would you re-challenge with docetaxel?

Or would you proceed with cabazitaxel or other therapy? Initial chemo-hormonal therapy was ADT + Docetaxel x6 cycles.Docetaxel rechallenge at time of ...

2 Answers available

Will you offer olaparib + abiraterone for all patients with metastatic castrate resistant prostate cancer based on results of PROPEL trial?

Do you find the ibPFS endpoint sufficient to change practice for any or all patients, or will you await OS or other data/trials?

2 Answers available

For unfavorable intermediate prostate cancer in elderly patients, would you consider radiation without ADT?

2 Answers available

Given several PARP inhibitors approved or with emerging positive data in castrate resistant prostate cancer, how do you decide which one and when to use?

How do you differentiate between olaparib, rucaparib, niraparib, talazoparib?

2 Answers available

For a patient treated with abiraterone for first line metastatic prostate cancer, would you still use a combination of abiraterone/olaparib at a subsequent progression?

If yes, would you directly add olaparib at progression on abiraterone vs waiting to use abi/olaparib at a later line of therapy?

2 Answers available

Among non-HRRm castrate resistant prostate cancer patients, are there features predictive of response to PROPEL regimen of abiraterone/olaparib?

3 Answers available

What could explain the discordant results between PARP/abiraterone combinations in MAGNITUDE and PROpel in non-HRRm prostate cancer?

Is the benefit in PROpel driven by BRCA1/2 or ATM mutated tumors vs all comers?

1 Answer available

How would you treat node positive (pN+) prostate cancer with undetectable post-op PSA after radical prostatectomy and pelvic LND?

Would you offer adjuvant radiation? (Dose? Target?) vs Salvage? Would you add ADT? Would you add abiraterone? Would the number of lymph nodes involv...

3 Answers available

Would you treat a patient with metastatic castration resistant prostate cancer and prior treatment with Ra-223 with Lu-117-PSMA-617 therapy?

Is prior Ra-223 a contraindication for treatment?

1 Answer available

What can prostate patients do for sexual function while on ADT?

4 Answers available

Would you ever recommend testosterone replacement for men with incomplete T recovery after ADT for prostate cancer?

Patient has ED unresponsive to cialis/viagra; would you recommend testosterone replacement therapy?

5 Answers available

How does urinary obstruction impact your choice of therapy for metastatic or locally advanced prostate cancer?

1 Answer available

In high or very high risk prostate cancer, do you utilize combined androgen blockade in patients receiving definitive RT?

Do you have a preference for bicalutamide? Can abiraterone be used instead?

6 Answers available

At what PSA level would you consider restaging a patient who was treated with ADT and radiation and had undetectable PSA?

At what PSA would you become suspicious for biochemical recurrence and pursue restaging? Is there a threshold value? What imaging modality would you ...

2 Answers available

When would you use PSMA PET over conventional imaging for prostate cancer?

Would you use it for initial staging or at time of biochemical recurrence?

2 Answers available

Do you treat de novo metastatic hormone sensitive prostate cancer presenting with a paraneoplastic syndrome more aggressively?

1 Answer available

Do you consider estrogen patches in treatment of prostate cancer?

2 Answers available

Can abiraterone or enzalutamide be substituted for bicalutamide to prevent a flare when initiating ADT with a GnRH agonist for metastatic prostate cancer?

1 Answer available

Would you give ADT + docetaxel -> darolutamide for a low risk castrate sensitive metastatic prostate cancer patient given ARASENS results?

The trial inclusion criteria was essentially "docetaxel candidate per the treating oncologist"

2 Answers available

Would you consider de-escalating abiraterone in a patient treated with ADT/abiraterone/prednisone for metastatic hormone sensitive prostate cancer who has had an excellent response with undetectable PSA and minimal side effects for over 2 years?

Is there a concern regarding rarer side effect emergence (cardiac, bone, muscle, cognitive) of long term exposure to "maximal" androgen deprivation? I...

2 Answers available

Based on the STAMPEDE trial pooled analysis, which patients with high risk prostate cancer would you add abiraterone for 2 years?

3 Answers available

How do PSMA PET positive nodes change your treatment recommendations after RP?

Would you consider boosting the nodes? What dose? Would this change your recommendation for length of ADT?

2 Answers available

How would you treat a patient with prostate cancer with de novo bone and bone marrow metastases with cytopenias?

Would you consider chemotherapy, androgen blockade or triple therapy (chemo and AR targeting)?

1 Answer available

What are your top takeaways from ASCO GU 2022?

6 Answers available

Would you consider addition of docetaxel to abiraterone and ADT in metastatic hormone senstive prostate cancer patients who progress on ADT and abiraterone?

Would the results of PEACE-1 trial justify this?

2 Answers available

Would you change treatment in a patient with metastatic CRPC on PARP inhibitor with rising PSA but negative Axumin PET scan?

2 Answers available

Do you consider ADT intensification with enzalutamide or abiraterone in patients receiving adjuvant radiation with ADT?

Are there clinical features (post-op PSA, Decipher score, pN+, pT3, etc) that would inform your decision?

2 Answers available

Do you hold ADT before work up for prostate cancer when ordering advanced imaging such as PSMA PET?

Do you worry about false negatives on PET, CT, MRI if ADT is started before the scan? Scheduling scans can sometimes book 2-4 weeks out.

2 Answers available

For metastatic prostate cancer, when would you add carboplatin to docetaxel or cabazitaxel?

1 Answer available

What is your preferred therapy for CDK12-altered advanced prostate cancer, outside clinical trial?

Would you treat with PARP inhibitor or Check-Point Inhibitor?

1 Answer available

Do you recommend ADT or other systemic therapy in patients with rising PSA after prostatectomy and salvage RT and PSMA scan negative for metastatic disease?

2 Answers available

How would you treat a patient with Gleason 8 or 9 prostate cancer, pretreatment PSA 15-24, with retroperitoneal adenopathy?

Is there a role of EBRT to the prostate with extended fields to cover the retroperitoneal nodes plus ADT (definitive therapy) or would you treat as ca...

4 Answers available

How would you manage asymptomatic radiographic progression from M0 CRPC to M1 CRPC to bone?

PSA rose from 25 to 30 ng/mL over 6 months on darolutamide for M0 CRPC, prompting scans which showed oligometastatic disease to bone, not amenable to ...

1 Answer available

Would you consider PARP inhibition in a patient with metastatic prostate cancer and a germline BRCA2 variant of unknown significance?

Or would you restrict such treatment to patients with known pathogenic germline BRCA mutations?

1 Answer available

In addition to ADT, how would you treat Gleason 8, pure ductal prostate adenocarcinoma with oligometastatic disease?

Given ductal histology, is docetaxel preferred over NHT?

1 Answer available

Is there an absolute PSA level above which you would not recommend a radical prostatectomy for newly diagnosed prostate cancer despite the absence of metastatic disease with advanced imaging?

Are there other high or very high risk features that would also contribute to your decision making?

1 Answer available

Would you recommend surgery or radiation for newly diagnosed localized prostate cancer diagnosed on a urethral lesion biopsy?

GS 4+4. PSA low (1-2). CT and bone scan negative for lymphadenopathy or metastatic disease. Prostate MRI pending.

2 Answers available

Will you consider adding an AR targeted agent to ADT for a patient thought to have isolated pelvic nodal recurrence of prostate CA if next generation imaging reveals additional non-regional disease not seen on conventional imaging?

Patient previously had prostatectomy and salvage RT

1 Answer available

Would you continue or switch therapy for someone who progressed through AR directed therapy and has a rapid rise in PSA while receiving Ra-223 for bone-dominant castrate resistant prostate cancer?

1 Answer available

What is the best approach to organ confined squamous cell cancer of the prostate?

Would you recommend surgery first or neoadjuvant therapy such as concurrent cisplatin/RT or another regimen?

1 Answer available

Which patients with mCRPC on ADT + advanced anti-AR do you treat with bisphosphonates or denosumab?

Did you change your practice given the SRE results in the control arm of EORTC 1333 at ASCO 2021? When using bisphosphonates or denosumab, what dosin...

2 Answers available

How exactly would you utilize ADT via leuprolide or bicalutamide with salvage RT post prostatectomy with PSA >0.5?

2 Answers available

How and when are you using sipuleucel-T in metastatic prostate cancer given the increase in available treatment options?

Do prior treatments for mHSPC change your thinking on whether or not to use sipuleucel-T?

2 Answers available

What is your preferred choice and timing of systemic therapy in a patient with high risk oligometastatic prostate cancer undergoing metastasis directed therapy to all sites of disease, including the prostate?

1 Answer available

How would you treat high risk prostate adenocarcinoma who relapsed after RT and ADT with a very low PSA, widespread mets to bone and soft tissue who is progressing on ADT, docetaxel and carboplatin?

No targetable mutations detected

1 Answer available

How would you treat a patient with newly diagnosed prostate cancer with low volume bone metastases and extensive lung metastases with a very low PSA (< 5) and no neuroendocrine differentiation on pathology?

In addition to ADT, would you treat with abiraterone, enzalutamide or docetaxel? Or other treatment - platinum/taxane?

3 Answers available

How would you sequence 177LU-PSMA-617 with current therapies for men with mCRPC?

2 Answers available

Would you consider radical prostatectomy for a young male with unfavorable intermediate risk cT3a prostate cancer and PSMA PET concerning for regional lymph nodes involvement but negative conventional imaging?

Gleason 4+3=7 and PSA 4

3 Answers available

What are your treatment recommendations in a patient with de novo metastatic prostate adenocarcinoma with neuroendocrine differentiation?

1 Answer available

Do you consider tertiary grade pattern, LVI or PNI on prostatectomy specimens as adverse features to recommend EBRT and ADT for patients with unfavorable intermediate prostate CA after prostatectomy with undetectable PSA?

Are there other adverse features aside from seminal vesicle invasion, positive margins, or extraprostatic extension that you consider?

1 Answer available

After completing 6 cycles of docetaxel plus ADT for metastatic hormone-sensitive prostate cancer per CHAARTED, are there clinical scenarios in which you would add an additional AR targeted agent (ex: enzalutamide, abiraterone, or apalutamide) to ADT?

Does post docetaxel PSA influence your decision?

1 Answer available

For persistent PSA elevation after prostatectomy, would you recommend salvage radiation if pathologically negative nodes, but regional and non-regional lymphadenopathy on PSMA PET?

Specifically, would you offer salvage radiation to a patient who underwent a prostatectomy with PLND and had a post-op PSA of 12 with pathology reveal...

2 Answers available

How would you sequence therapies for a patient with chemotherapy-naive metastatic castration-resistant prostate cancer who is MSI-H on tissue-based NGS?

What line would you give pembrolizumab?

1 Answer available

Would you consider adding abiraterone or docetaxel in patients with high risk prostate cancer whose PSA does not become undetectable after ADT and radiotherapy with castrate level testosterone?

4 Answers available

When using active surveillance for rising PSA after prostatectomy, at what level of PSA would you start ADT?

2 Answers available

Are there any clinical scenarios where you would recommend adjuvant docetaxel for localized prostate cancer?

1 Answer available

What duration of ADT do you recommend for a patient with locally treated prostate cancer who undergoes metastasis-directed radiation therapy to a single oligometastatic bone lesion?

Would you add abiraterone or enzalutamide?

5 Answers available

In a patient with metastatic prostate cancer on abiraterone planning to start Radium-223, what is the minimum interval between the last dose of abiraterone and the first dose of Radium?

1 Answer available

What is your preferred treatment approach for a patient who has prostate cancer with disease only in retroperitoneal nodes, experiencing rapid biochemical progression on abiraterone, and who was previously treated with an androgen receptor inhibitor while non-metastatic?

1 Answer available

How would you manage a patient with localized prostate cancer treated with radical prostatectomy and found to have a single involved pelvic lymph node on final pathology and a detectable postoperative PSA?

2 Answers available

In what settings is Fluciclovine (Axumin) PET/CT best utilized in prostate cancer?

What clinical scenario(s) do you find results to be the most beneficial?

1 Answer available

Would you treat a patient with refractory, metastatic castrate resistant prostate cancer who has somatic ATM mutation with a PARP inhibitor?

Does the specimen (blood vs tissue) used to detect mutation affect your consideration?

1 Answer available

For patients with high-risk metastatic castration-sensitive prostate cancer who have completed upfront ADT + docetaxel, would you consider starting abiraterone or enzalutamide in addition to ADT while the disease is still castration-sensitive?

Are there particular populations in whom you would add an AR targeted agent after docetaxel?

6 Answers available

Which of the androgen blocking agents have the best CNS penetration for someone with metastatic CRPC with brain metastases?

Assuming patient received appropriate local therapy for brain metastases, which agent would you use?

1 Answer available

Which patients would you treat with relugolix instead of injectable GnRH agonist therapy?

HERO study - https://clinicaltrials.gov/ct2/show/NCT03085095

1 Answer available

What is your treatment approach for metastatic squamous carcinoma of the prostate?

1 Answer available

How do you decide between abiraterone or docetaxel for first line treatment of newly diagnosed metastatic prostate cancer?

Given that ADT + abiraterone and ADT + docetaxel have not been directly compared.

2 Answers available

Would you introduce AR targeted therapy if a patient has already been successfully treated with LHRH for low risk, low volume metastatic hormone sensitive prostate cancer?

What is the time window in which you would consider adding AR targeted therapy? Is there a time frame in which you would NOT consider introducing sin...

2 Answers available

Would you treat prostate cancer with hormone sensitive metastatic recurrence (after local treatment) the same as de novo metastatic hormone sensitive disease?

1 Answer available

Do you offer adjuvant chemotherapy or abiraterone for patients with high and very high risk prostate cancer with still detectable PSA after radical prostatectomy and lymph node dissection?

2 Answers available

Would you retreat a patient with docetaxel for metastatic castrate resistant prostate cancer if treated in hormone sensitive setting (metastatic disease) with good response three years ago but now has CRPC and has progressed on abiraterone?

2 Answers available

What is the preferred steroid regimen for metastatic prostate cancer patients on docetaxel?

Is there an optimal strategy to minimize unnecesary steroid use?For example, pre-treatment dexamethasone or 3 day dexamethasone? Prednisone only conti...

1 Answer available

Would you give abiraterone in the post-prostatectomy setting to patients with positive nodes detected at surgery?

Is there data and FDA approval for this indication? What about for nodal failure after radiation?

1 Answer available

Would you treat a patient with Radium 223 for prostate cancer with mainly bone metastasis if he has a history of osteonecrosis of the jaw bone from bisphosphonate/Denosumab?

1 Answer available

How do you think about management options in a patient with a minute focus of Gleason grade 4 (4+4) on 1 core from needle biopsy along with only Gleason 3+3 disease in other biopsy cores and PSA<10?

Assuming patient is not a surgical candidate and wishes to pursue definitive radiotherapy, what duration of ADT would you give?

1 Answer available

How would you treat a patient with metastatic small cell of the prostate who is progressing on cisplatin/etoposide and has previous NGS without actionable mutations?

2 Answers available

Would you treat unfavorable intermediate risk prostate cancer in the setting of recently resected NSCLC?

How would a much higher risk cancer affect decision making? How would you treat him?

3 Answers available

Is there a role of definitive radiation or prostatectomy, in a patient who has M0 castrate resistant prostate cancer and whose PSA is undetectable on ADT and enzulatamide?

2 Answers available

What is your approach to imaging for localization of biochemical relapse of prostate cancer after radical prostatectomy?

Abstract 5014 at ASCO annual meeting 2019 showed superiority of PSMA-PET imaging over fluciclovine-PET imaging. Are you utilizing these speciali...

1 Answer available

For recurrent prostate cancer after definitive radiation, how do you guide patients between the various salvage options vs ADT?

1 Answer available

How does your management change for patients with bone marrow failure due to a metastatic solid tumor to the marrow?

Do you offer EPO and TPO support? Do you modify your systemic therapy up front or after subsequent cycles?

1 Answer available

In a patient with M0CRPC with PSA doubling time < 6 months, will you wait until the absolute PSA value is >2, or is PSADT alone sufficient to start an AR targeted agent?

In the SPARTAN trial, median PSA at study entry was ~ 7. Does the MFS benefit extend to patients with low PSA(< 2 or < 1)?

3 Answers available

What is the optimal duration of ADT for cN1 disease with EBRT?

3 Answers available

Would you offer PA nodal XRT in a patient with rising PSA and multiple PET positive nodes after previous prostate XRT treatment that is otherwise locally controlled?

For instance, if the fluclicovine scan shows a few small avid nodes not only in the pelvis but extending to the paraaortic region, would you treat the...

2 Answers available

What duration of ADT do you recommend for patients with high risk or very high risk prostate cancer who undergo radical prostatectomy, adjuvant RT, and adjuvant docetaxel?

1 Answer available

For a very high risk prostate cancer with relatively no elevation in PSA but no distant or nodal metastasis would you consider “neoadjuvant” ADT and chemotherapy prior to EBRT?

In this case, Gleason 5+5 in all cores, clinical T4.

1 Answer available

In a patient with intermediate risk castration sensitive prostate cancer S/P prostectomy and now with biochemical recurrence + regional lymph node involvement 8 months post RP, would you do hormonal therapy (ADT or ADT+Abiraterone) with or without EBRT?

1 Answer available

Should enzalutamide be given concurrently with Sip-T in castration-resistant metastatic prostate cancer?

2 Answers available

How do you manage androgen deprivation in a patient with oligometastatic prostate cancer in which the primary and all known metastatic sites have been treated with curative intent radiation and PSA remains undetectable?

How long would you continue androgen deprivation after radiation?

2 Answers available

Are the cardiac risks of LHRH agonists also seen in patients undergoing bilateral orchiectomy for ADT in hormone-sensitive prostate cancer?

1 Answer available

Has the role of radium-223 changed in the treatment of prostate cancer given the availability of newer anti-androgen medications to treat metastatic prostate cancer?

2 Answers available

How much emphasis do you place on anti-AR therapy in a patient with metastatic castration resistant prostate adenocarcinoma with progressive neuroendocrine differentiation?

In a patient with a prior response to ADT and progression on taxane and platinum chemotherapy, would you consider AR directed therapy?

1 Answer available

Would you recommend Radium-223 for extensive bone disease in a prostate cancer patient with adenopathy >3cm?

Per the ALSYMPCA study, they excluded patients with > 3cm lymphadenopathy. Patient is currently on enzalutamide and leuprolide and refuses docetaxe...

1 Answer available

Is there a role for docetaxel for men with high risk prostate cancer receiving radiation and androgen deprivation therapy?

Does the STAMPEDE trial, showing a survival benefit with the addition of docetaxel to standard treatment, change the standard of care for high risk, n...

4 Answers available

How many cycles of docetaxel do you give to patients with metastatic castration resistant prostate cancer?

1 Answer available

For a patient with metastatic castration-resistant prostate cancer to the bones with rising PSA but no evidence of radiographic or symptomatic progression, would you continue with the same treatment or change therapy based on biochemical progression?

Assuming there was an initial period of response to the mCRPC treatment.

1 Answer available

Would you add atezolizumab to carboplatin + etoposide for small cell/neuroendocrine prostate cancer?

Treatment for small cell/neuroendocrine prostate is extrapolated from data on small cell lung cancer. It now appears that Carboplatin + Etoposide + At...

1 Answer available

How do you manage surveillance imaging for patients with metastatic castration-resistant prostate cancer?

Are you directed by symptoms, PSA changes or do you have a standard schedule regardless of those factors?

1 Answer available

How do you treat newly diagnosed low volume metastatic hormone sensitive prostate cancer in light of new data from STAMPEDE presented at ESMO 2018?

Abstract LBA5_PR ‘Radiotherapy (RT) to the primary tumour for men with newly-diagnosed metastatic prostate cancer (PCA): survival results from S...

1 Answer available

In view of possible equivalent efficacy of low dose abiraterone with food, has anyone had clinical experience offering low dose abiraterone to spare patients from financial toxicity of abiraterone?

Prospective International Randomized Phase II Study of Low-Dose Abiteraterone with Food versus Standard Dose Abiraterone In Castration-Resistant Prost...

1 Answer available

Is it acceptable defer or forgo biopsy and to start androgen deprivation therapy in an elderly, fragile patient with PSA in the 900s and evidence of bone metastases?

1 Answer available

When is the best time to start denosumab in men with metastatic prostate cancer?

Should it be started at the initial diagnosis of bone mets?

2 Answers available

How do you approach non-metastatic castration-resistant prostate cancer?

For which patients would you consider addition of apalutamide or enzalutamide? How do you decide between the 2 drugs?

2 Answers available

How would you approach a patient with M0 castrate-resistant prostate cancer started on enzalutamide who continues to have increasing PSA levels without metastases seen on imaging?

NCCN recommends to change therapy or maintain current therapy in this setting without further clarification. What thresholds would cause a change in t...

1 Answer available

How do you manage a patient with metastatic prostate cancer who does not acheive a PSA response to upfront ADT?

1 Answer available

How do you approach a patient with a non-castrate testosterone level and rising PSA despite receiving LHRH agonist therapy?

1 Answer available

Would you use AR-V7 testing to decide second-line androgen receptor-axis-targeted therapy vs chemotherapy for patients who with metastatic castration-resistant prostate cancer?

If yes, what factors push you to test for AR-V7 or would you test all patients in this clinical scenario?

3 Answers available

What approach would you take for patients with metastatic castration-resistant prostate cancer with marked PSA response (undetectable) on docetaxel, but radiographic progression in bone metastases?

1 Answer available

How would you treat a patient with high-volume metastatic prostate cancer who has asymptomatic biochemical relapse after having a good response to upfront docetaxel?

Would you initiate abiraterone or enzalutamide for the rising PSA or wait until the patient is symptomatic or has a new site of metastasis?

1 Answer available

How do you manage musculoskeletal pain in men receiving androgen deprivation therapy for non-metastatic prostate cancer?

In patients with new bone pain and without any evidence of bone metastases receiving GnRH agonists, how do you manage pain symptoms?

1 Answer available

If a patient with non-metastatic prostate cancer is found to have a BRCA mutation, should this influence treatment recommendations for local therapy?

2 Answers available

How do you approach isolated recurrence in a para-aortic lymph node following definitive radiation for localized prostate cancer?

Is there a role for salvage LN dissection or salvage RT to the node? And is there a role for systemic therapy (ADT or chemotherapy) in addition? If yo...

1 Answer available

Do you counsel patients on the risk of dementia following androgen deprivation therapy for prostate cancer?

Two retrospective studies from Stanford showed that patients who received ADT had an increased risk of dementia and Alzheimer's. Is this finding ...

3 Answers available

When do you initiate androgen deprivation therapy for biochemical relapse of prostate cancer following primary therapy?

Do you use a PSA threshold, PSA doubling time, or only evidence of metastatic disease to trigger ADT? For those without rapid doubling time, do you ev...

1 Answer available

What duration of androgen deprivation therapy do you use for patients with pN+ prostate cancer undergoing upfront adjuvant RT after a radical prostatectomy and pelvic lymph node dissection?

Do other factors (i.e. Gleason score, pretreatment PSA, or pT stage) affect your decision?

2 Answers available

In light of CHAARTED and STAMPEDE, should all men with newly-diagnosed, treatment-naive metastatic prostate cancer be treated with chemohormonal therapy?

1 Answer available

Which, if any, aspects of your management of prostate cancer differ in your African-American patients versus those of other racial/ethnic backgrounds?

Given recent advancements in the understanding of biological differences in prostate cancer patients of African vs. other ancestry, does your manageme...

1 Answer available

For patients eligible for and considering active surveillance for low-risk prostate cancer, do you routinely use tests for molecular risk stratification?

Are there specific subsets for whom these results should change management?

1 Answer available

Do you routinely offer AR-v7 testing to determine whether to treat with chemotherapy versus enzalutamide or abiraterone in metastatic castration resistant prostate cancer?

2 Answers available

Do you routinely include sipuleucel-T as one of your lines of systemic therapy for metastatic castration resistant prostate cancer?

If so, how do you sequence this with other therapies? In addition, in the absence of an effect on radiographic PFS or serum PSA, how do you asse...

1 Answer available

Which PET imaging modality, if any, is preferred to work up possible nodal involvement or local recurrence in prostate cancer?

In situations where there is a significant risk of either local or nodal persistence/recurrence post prostatectomy with a rising PSA, or nodal involve...

1 Answer available

For castration-naive metastatic prostate cancer patients who you plan to treat with LHRH agonist monotherapy, how long do you treat with an anti-androgen therapy prior to and after initiating the LHRH-agonist?

A recent systematic review suggested that disease progression owing to a testosterone "flare" may not be a real phenomenon: http://www.ncbi.nlm.nih.go...

1 Answer available

Is there a role for adjuvant docetaxel in patients with high-risk localized prostate cancer who elect for prostatectomy?

The role of adjuvant docetaxel with ADT following RT for high risk disease has been previously elucidated by RTOG 0521. Following prostatectomy,...

1 Answer available

Following presentation of the PRINCE at ASCO 2016, should we be offering intermittent docetaxel to patients with metastatic castration-resistant prostate cancer?

At the ASCO 2016 annual meeting, results of the PRINCE trial were reported. A strategy of intermittent docetaxel was found to be non-inferior to conti...

1 Answer available

When should intermittent androgen deprivation vs continuous androgen deprivation be used for the treatment of prostate cancer?

In a patient with node positive disease, treated definitively with radiation, should continuous or intermittent ADT be administered? If a patien...

1 Answer available

Is there any role for radium-223 early in the course of castration-resistant prostate cancer with bone metastases?

Typically radium-223 is reserved for men with symptomatic bone disease after failure of multiple other therapies. Is there a population of men w...

1 Answer available

Should bone-directed agents, such as denosumab or zoledronic acid, be given when patients are being treated with radium-223?

1 Answer available

At what point would Radium-223 dicholoride treatment be the best management for a patient with established metastatic prostate cancer with an elevated PSA and symptomatic bone pain with corresponding bone lesions on imaging?

1 Answer available

When should SBRT be offered to oligometastatic bone disease in a patient with prostate cancer?

What factors should be considered with offering SBRT to oligometastatic bone disease in prostate cancer patients? Should this been done off of a proto...

2 Answers available

Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-04-10

Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).

Lancet, 2016 Mar 19

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

Eur. Urol.,

Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2015-09-01

A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.

Eur Urol, 2015 Jul 16

Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis.

BJU Int, 2009 Feb

Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial.

European urology, 2014-06

Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.

The New England journal of medicine, 2013-07-18

Alpha emitter radium-223 and survival in metastatic prostate cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-10

Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-01-20

Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details.

The New England journal of medicine, 2004-10-07

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

JAMA oncology, 2016-11-01

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.

J. Nucl. Med., 2015 Jun 25

Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-04-01

Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626.

Lancet Oncol., 2010-02-01

Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-03-20

Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7.

The Journal of urology, 2005-08

Parenteral medroxyprogesterone for the management of luteinizing hormone releasing hormone induced hot flashes in men with advanced prostate cancer.

Mol Clin Oncol, 2015 May 04

Bee pollen and honey for the alleviation of hot flushes and other menopausal symptoms in breast cancer patients.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-12-10

Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-11-10

Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer.

The Journal of urology, 1999-07

Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer.

Annals of oncology : official journal of the European Society for Medical Oncology, 2009-03

A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB).

Mayo Clin Proc, 2004 Oct

Pilot evaluation of paroxetine for treating hot flashes in men.

JNCI Cancer Spectr, 2019 Oct 21

Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603).

N Engl J Med, 1994 Aug 11

Megestrol acetate for the prevention of hot flashes.

The New England journal of medicine, 2018-05-03

Oxybutynin for Hot Flashes Due to Androgen Deprivation in Men.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-08-01

Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-06-20

Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment.

The Journal of urology, 2002-09

Impact of previous local treatment for prostate cancer on subsequent metastatic disease.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2009-01-15

Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence.

Nature, 2005-12-08

VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche.

J Clin Oncol, 1999 Jul

Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study.

Lancet, 2015 Jan 3

Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial.

The New England journal of medicine, 2001-12-06

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Lancet, 2001-09-22

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.

Breast Cancer Res. Treat., 2010-02-01

Impact of breast surgery on survival in patients with distant metastases at initial presentation: a systematic review of the literature.

The Journal of urology, 1982-06

Treatment of a metastatic prostate derived tumor with surgery and chemotherapy.

Cancer research, 2000-04-15

Irradiation of a primary tumor, unlike surgical removal, enhances angiogenesis suppression at a distal site: potential role of host-tumor interaction.

J. Clin. Oncol., 2009-04-01

Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer.

Oncol. Rep., 2015-12-01

Surgical cytoreduction of the primary tumor reduces metastatic progression in a mouse model of prostate cancer.

Nat Commun, 2015-04-01

Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer.

PLoS ONE, 2016-01-01

Does Radiotherapy for the Primary Tumor Benefit Prostate Cancer Patients with Distant Metastasis at Initial Diagnosis?

J. Urol., 2002-04-01

Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis.

Lancet Oncol., 2015 Sep 09

Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial.

European urology, 2018-02

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

Lancet, 2018 Oct 18

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.

The Lancet. Oncology, 2006-06

Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-06-20

Course and Predictors of Cognitive Function in Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-02-20

Androgen Deprivation Therapy and Future Alzheimer's Disease Risk.

JAMA oncology, 2016-04

Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer.

JAMA oncology, 2017-01-01

Association Between Androgen Deprivation Therapy and Risk of Dementia.

JCO Precision Oncology, 2017 May 31

Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making

The New England journal of medicine, 2016-08-04

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.

NEJM Evidence, 2022 Jun 3

Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer

The New England journal of medicine, 2018-04-12

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.

The New England journal of medicine, 2018-06-28

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.

The New England journal of medicine, 2015-08-20

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-06-10

External Validation of the Benefit of Adjuvant Radiotherapy for Pathologic N1M0 Prostate Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-12-10

Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer.

JAMA Oncol,

Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial.

J Urol,

Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone.

Urology, 2013-06

Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-08-20

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

N. Engl. J. Med., 2019 Jun 02

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

Nat Rev Urol, 2014 Apr

Small cell carcinoma of the prostate.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2013-07-01

Platinum-based chemotherapy for variant castrate-resistant prostate cancer.

N Engl J Med, 2010 Jul 29

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

N. Engl. J. Med., 2017-07-27

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-04-10

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2016-03-15

Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers.

Prostate Int,

Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-05-10

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-05-10

Low-Fat Abiraterone Food Effect Is of Little Consequence.

Nat Rev Urol, 2017 Dec 12

HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer.

Lancet, 2021 Dec 23

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.

The New England journal of medicine, 2017-07-27

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.

Ann. Oncol.,

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.

The Lancet. Oncology, 2013-08

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.

Eur Urol, 2017 Oct 23

Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.

J Clin Oncol, 2017 Jul 28

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.

N. Engl. J. Med., 2019 May 31

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.

J. Clin. Oncol., 2019 Jul 22

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.

Lancet Oncol, 2019 Apr 12

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.

AJR. American journal of roentgenology, 2019-10

Fluorine-18-Labeled Fluciclovine PET/CT in Clinical Practice: Factors Affecting the Rate of Detection of Recurrent Prostate Cancer.

JAMA oncology, 2019-06-01

Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.

Clin Nucl Med,

A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT.

The Lancet. Oncology, 2019-03

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.

JAMA Oncol,

Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial.

European urology, 2018-08

Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer.

N. Engl. J. Med., 2019 Sep 30

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.

Lancet,

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Eur. Urol., 2018 Jul 03

Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial.

Lancet, 2019 Apr 11

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.

J. Clin. Oncol., 2017 Dec 14

Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.

Eur. Urol., 2019 Jul 19

Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.

Lancet, 2008 Dec 16

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

Lancet, 2011-12-17

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.

J Thorac Oncol. , 2019 Oct 17

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort.

Cancer, 2020 Feb 19

Validation of a subclassification for high-risk prostate cancer in a prospective cohort.

Clin Genitourin Cancer, 2019 Mar 13

Use of Radium-223 Dichloride in Patients With Osteonecrosis of the Jaw Induced by Zoledronic Acid: Report of 2 Cases.

N. Engl. J. Med., 2020 May 29

Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2012-12-15

Cabazitaxel: more than a new taxane for metastatic castrate-resistant prostate cancer?

Cabazitaxel in castration resistant prostate cancer with brain metastases: 3 case reports.

BMC Cancer, 2014 Sep 15

Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial.

JAMA Oncol,

Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.

Eur Urol, 2019 Feb 28

Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005-02-01

Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31.

Urology, 2001-08

Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer.

The New England journal of medicine, 2017-02-02

Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.

Lancet Oncol., 2016-06-01

Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.

JAMA Oncol, 2020 Mar 26

Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer.

Lancet, 2020 Sep 28

Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial.

Lancet Oncol,

Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial.

Lancet Oncol,

Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-11-01

ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.

JAMA Oncol, 2021 Feb 18

Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.

The New England journal of medicine, 2012-09-06

Intermittent androgen suppression for rising PSA level after radiotherapy.

Radiother Oncol, 2020 Apr 01

Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer.

The Lancet. Oncology, 2012-02

Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials.

International journal of radiation oncology, biology, physics, 2016-11-01

Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality.

Cancer, 2018-07-15

Three-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-02-01

Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.

Oncologist, 2020 Dec 03

Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer.

Urology, 2000-11-01

Proximity of prostate cancer to the urethra: implications for minimally invasive ablative therapies.

Abdom Radiol (NY), 2019 Aug 29

Apical periurethral transition zone lesions: MRI and histology findings.

Lancet, 2021 May 07

F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial.

N. Engl. J. Med., 2016-10-13

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.

J Urol, 2020 Apr 13

Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer. Reply.

Eur J Nucl Med Mol Imaging, 2020 Aug 12

Pelvic lymph-node staging with F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial.

J Urol,

Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with Ga-PSMA Positron Emission Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node Pathology.

N. Engl. J. Med., 2009-06-11

Duration of androgen suppression in the treatment of prostate cancer.

Lancet Oncol, 2010 Oct 07

External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-04-10

Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.

Prostate Cancer Prostatic Dis, 2020 May 13

Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.

The Lancet. Oncology, 2018-11

Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.

The Prostate, 2019-09

Genomic and clinical characterization of pulmonary-only metastatic prostate cancer: A unique molecular subtype.

J Urol, 2020 Dec 28

Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.

Lancet Oncol, 2020 Mar 27

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.

Clinical genitourinary cancer, 2018-06

Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy.

Cancer treatment and research communications, 2019

Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer.

Prostate Cancer Prostatic Dis, 2020 Feb 28

Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry.

Cancer, 2019 Dec 1

Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.

Nat Rev Urol, 2021 Apr 06

Optimizing the diagnosis and management of ductal prostate cancer.

Eur Urol, 2020 Dec 03

Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies.

Pancreas, 2010-08

The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas.

American journal of clinical and experimental urology, 2014

Neuroendocrine differentiation of prostate cancer: a review.

The Prostate. Supplement, 1998

Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma.

The Prostate, 2001 May 15

Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients.

Clinical nuclear medicine, 2017 Jan

PET/CT With 68Ga-DOTA-TATE for Diagnosis of Neuroendocrine: Differentiation in Patients With Castrate-Resistant Prostate Cancer.

The New England journal of medicine, 2019-03-28

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.

Clin Cancer Res, 2019 Sep 11

Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.

Lancet Oncol, 2019 Oct 16

Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial.

JAMA Oncol,

Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial.

J Urol, 2021 Feb 26

A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with F-DCFPyL in Prostate Cancer Patients (OSPREY).

Journal of the National Comprehensive Cancer Network : JNCCN, 2014-05

Intermittent versus continuous androgen deprivation therapy.

Proceedings of the National Academy of Sciences of the United States of America, 2011-06-07

Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017-01

68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience.

European journal of nuclear medicine and molecular imaging, 2018-11

Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer.

European urology oncology, 2018-05

Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.

J Nucl Med, 2021 Dec 16

Predictors of F-DCFPyL-PET/CT Positivity in Patients with Biochemical Recurrence of Prostate Cancer After Local Therapy.

J Nucl Med, 2018 Dec 14

Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade.

Eur J Nucl Med Mol Imaging, 2019 Nov 15

The effect of androgen deprivation therapy on Ga-PSMA tracer uptake in non-metastatic prostate cancer patients.

Eur J Nucl Med Mol Imaging, 2019 Dec 26

Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with Ga-PSMA-11 PET/MRI in men with treatment-naïve prostate cancer.

JAMA Oncol,

Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial.

J Urol, 2021 Feb 03

The Predictive Value of Preoperative Negative Prostate Specific Membrane Antigen Positron Emission Tomography Imaging for Lymph Node Metastatic Prostate Cancer.

J Nucl Med, 2020 Jan 10

Impact of Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study.

Clin Cancer Res, 2021 Feb 23

Diagnostic Performance of F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study.

N Engl J Med, 2020 Apr 28

Olaparib for Metastatic Castration-Resistant Prostate Cancer.

Prostate cancer and prostatic diseases, 2018-04

Platinum sensitivity in metastatic prostate cancer: does histology matter?

JCO Precis Oncol, 2020

Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations.

Lancet Oncol, 2019 Sep 09

Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-11-01

Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy.

BJU international, 2014-12

Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.

The Journal of urology, 2002-09

Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer.

Lancet, 2020 Sep 28

Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data.

BMC cancer, 2019-06-13

A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA).

J Clin Oncol, 2022 Mar 15

Adjuvant Versus Early Salvage Radiation Therapy After Radical Prostatectomy for pN1 Prostate Cancer and the Risk of Death.

N Engl J Med, 2022 Feb 17

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.

Prostate, 2022 Jun 08

The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.

Br J Cancer, 2008 Feb 12

Parenteral oestrogen in the treatment of prostate cancer: a systematic review.

Lancet,

Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.

Eur Urol, 2015 Dec 17

A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol.

BJU Int, 2016 Nov 12

Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer.

International journal of radiation oncology, biology, physics, 2006-07-15

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

J Nucl Med, 2021 Jun 24

Lu-Prostate-Specific Membrane Antigen Ligand After Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience.

Oncotarget, 2017 Feb 25

Radioligand therapy of metastatic prostate cancer using Lu-PSMA-617 after radiation exposure to Ra-dichloride.

Eur Urol, 2020 Jun 09

Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial.

JAMA Oncol,

Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate.

BJU Int, 2022 Apr 03

Development and validation of a life expectancy calculator for US patients with prostate cancer.

Int J Radiat Oncol Biol Phys, 2020 Sep 11

Absolute versus Relative Benefit of Androgen Deprivation Therapy for Prostate Cancer: Moving Beyond the Hazard Ratio to Personalize Therapy.

Lancet Oncol, 2022 Jan 17

Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis.

Prostate Int, 2019 Feb 22

The role of prostate-specific antigen density in men with low-risk prostate cancer suitable for active surveillance: results of a prospective observational study.

J Clin Oncol, 2021 Jan 26

Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial.

J Urol, 2019 Sep 06

Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer.

Lancet,

The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.

AJR Am J Roentgenol, 2022 Jun 29

Head-To-Head Comparison of Ga-PSMA-11 PET/CT and Tc-MDP Bone Scintigraphy for the Detection of Bone Metastases in Patients With Prostate Cancer: A Meta-Analysis.

Eur Radiol, 2022 Aug 08

Validating the screening criteria for bone metastases in treatment-naïve unfavorable intermediate and high-risk prostate cancer - the prevalence and location of bone- and lymph node metastases.

Urology,

Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer.

Clin Nucl Med,

Comparing 99mTc-PSMA to 99mTc-MDP in Prostate Cancer Staging of the Skeletal System.

Skeletal Radiol, 2014 May 20

Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis.

Eur J Nucl Med Mol Imaging,

The flare phenomenon: still learning after 35 years.

International journal of radiation oncology, biology, physics, 2019-06-01

Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer.

Eur Urol, 2021 Apr 03

Impact of Definitive Local Therapy in Men with Primary Small Cell Prostate Carcinoma.

Lancet Oncol, 2013 Jan 04

2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.

Int. J. Radiat. Oncol. Biol. Phys., 2017-06-01

Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.

Radiother Oncol, 2012 Feb 16

Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer.

Lancet Oncol, 2021 Jan 18

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.

Prostate Cancer Prostatic Dis, 2021 Feb 10

Clinical considerations for the management of androgen indifferent prostate cancer.

Prostate Cancer Prostatic Dis, 2022 Mar 15

A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer.

J Urol, 2019 01

Clinical Usefulness of Total Length of Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer.

Urology, 2021 Oct 06

Variation of Serum PSA Levels in COVID-19 Infected Male Patients with Benign Prostatic Hyperplasia (BPH): A Prospective Cohort Studys.

Eur Urol Oncol, 2020 Aug 15

Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial.

JAMA Netw Open, 2021 Jul 01

Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy.

JAMA, 2005-09-14

Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.

JAMA oncology, 2018-06-14

Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial.

Int J Radiat Oncol Biol Phys, 2021 Nov 03

Salvage Low-Dose-Rate Prostate Brachytherapy: Clinical Outcomes of a Phase 2 Trial for Local Recurrence after External Beam Radiation Therapy (NRG Oncology/RTOG 0526).

Eur Urol, 2021 Dec 23

Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer.

Int J Radiat Oncol Biol Phys, 2000 Sep 01

Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients.

Radiother Oncol, 2021 Feb 13

Predictors for post-treatment biopsy outcomes after prostate stereotactic body radiotherapy.

J Clin Oncol, 2023 Apr 27

Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial.

Front Oncol, 2022 Mar 29

Urethra Sparing With Target Motion Mitigation in Dose-Escalated Extreme Hypofractionated Prostate Cancer Radiotherapy: 7-Year Results From a Phase II Study.

Brachytherapy, 2022 May 04

Detection of failure patterns using advanced imaging in patients with biochemical recurrence following low-dose-rate brachytherapy for prostate cancer.

Pract Radiat Oncol, 2023 Jul 11

A Phase I Trial of Focal Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer.

Nature reviews. Urology, 2018-04

Clinical implications of PTEN loss in prostate cancer.

N Engl J Med, 2021 Jun 23

Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

Lancet, 2019 Jun 18

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.

Int J Radiat Oncol Biol Phys, 2015 Jul 15

A Phase 1/2 Trial of Brief Androgen Suppression and Stereotactic Radiation Therapy (FASTR) for High-Risk Prostate Cancer.

J Clin Oncol, 2019 Dec 12

Sequencing of Androgen-Deprivation Therapy With External-Beam Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial.

J Clin Oncol, 2021 Jan 10

Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis.

J. Clin. Oncol., 2016-05-20

Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991.

Lancet Oncol., 2018 Dec 19

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.

Lancet Oncol, 2015 Feb 19

High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.

Eur J Cancer, 2020 Dec 03

Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial.

Prostate, 2020 Feb

Correlation between cribriform/intraductal prostatic adenocarcinoma and percent Gleason pattern 4 to a 22-gene genomic classifier.

BJUI Compass, 2021 Jan 05

Ductal adenocarcinoma of the prostate: A systematic review and meta-analysis of incidence, presentation, prognosis, and management.

Lancet, 2022 Apr 08

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-05-10

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.

Eur Urol Oncol, 2022 May 20

Treatments for Metastatic Hormone-sensitive Prostate Cancer: Systematic Review, Network Meta-analysis, and Benefit-harm assessment.

J Clin Oncol, 2021 Dec 20

Int J Radiat Oncol Biol Phys, 2023 May 02

Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial.

J Clin Oncol, 2023 Mar 23

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.

The Lancet. Oncology, 2018-02

Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.

Lancet Oncol, 2019 Dec

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.

The Lancet. Oncology, 2019 Sep 29

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021 Nov 10

Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.

Annals of oncology : official journal of the European Society for Medical Oncology, 2023 Jul 01

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial.

Lancet (London, England), 2023 Jun 04

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.

Eur Urol, 2018 Sep 25

Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial.

Eur Urol, 2015 May 21

Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives.

JAMA oncology, 2023 Jun 01

Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial.

International journal of radiation oncology, biology, physics, 2019-08-01

Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials.

Lancet, 2021 Feb 11

[Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.

Eur J Nucl Med Mol Imaging, 2023 Jul 05

The significance of metabolic response to neoadjuvant androgen deprivation therapy detected with [Ga]Ga-PSMA-11-PET/CT in high-risk prostate cancer patients treated with definitive radiotherapy.

BJU Int, 2021 Dec 13

The clinical characteristics of patients with primary non-prostate-specific membrane antigen-expressing prostate cancer on preoperative positron emission tomography/computed tomography.

J Urol, 2021 Jan 27

Outcomes of Post-Neoadjuvant Intense Hormone Therapy and Surgery for High Risk Localized Prostate Cancer: Results of a Pooled Analysis of Contemporary Clinical Trials.

Eur Urol, 2020 Jan 08

Veterans Affairs Cooperative Studies Program Study #553: Chemotherapy After Prostatectomy for High-risk Prostate Carcinoma: A Phase III Randomized Study.

Int J Radiat Oncol Biol Phys, 2019 Oct 10

Spinal Cord Dose Tolerance to Stereotactic Body Radiation Therapy.

EJNMMI physics, 2023 Feb 09

Investigation of image-based lesion and kidney dosimetry protocols for Lu-PSMA-I&T therapy with and without a late SPECT/CT acquisition.

The Lancet. Oncology, 2014-05

Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study.

The New England journal of medicine, 2023 Oct 19

Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.

Health and quality of life outcomes, 2020 May 12

How is the minimal clinically important difference established in health-related quality of life instruments? Review of anchors and methods.

European urology, 2015 Feb 14

Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results.

International journal of cancer, 2022 May 16

Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022 Oct 27

Safety and Survival Outcomes of Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior Ra treatment: The RALU Study.

The Lancet. Oncology, 2023 Sep 12

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.

Future oncology (London, England), 2023 Oct 26

TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer.

Cancer medicine, 2022 Jul 24

Hematological toxicities in PARP inhibitors: A real-world study using FDA adverse event reporting system (FAERS) database.

European urology, 2022 Apr 18

Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.

The New England journal of medicine, 2018-05-10

MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.

The New England journal of medicine, 2020 Mar 05

MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis.

J Clin Oncol, 2021 Jan 20

Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial.

JAMA oncology, 2023 Mar 01

Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020 Jan 10

Management of Patients with Renal Failure Undergoing Dialysis During I Therapy for Thyroid Cancer.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023 Jun 08

SNMMI Consensus Statement on Patient Selection and Appropriate Use of Lu-PSMA-617 Radionuclide Therapy.

Medical Oncology

Prostate Cancer

Questions discussed in this category

Papers discussed in this category

Related Topics in Medical Oncology